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ABSTRACT 
 
The Synthesis and Enzymatic Characterization of 6-amino-FMN with BluB; The Last Unsolved 
Biosynthetic Module of Vitamin B12 
 
Daniel J. Diaz 
Department of Chemistry 
Texas A&M University 
 
Research Advisor: Dr. Tadhg P. Begley 
Department of Chemistry 
 
The last unsolved module for the biosynthetic pathway of vitamin B12 is the biosynthesis of the 
lower axial ligand, dimethylbenzimidazole (DMB). Recently, the oxygen-dependent enzyme, 
BluB, has been shown to catalyze the oxidative fragmentation of coenzyme B2, FMN, and 
produces dimethylbenzimidazole (DMB), erythrose-4-phosphate, and alloxan. BluB is the first 
enzyme shown to utilize FMN as a substrate rather than as a coenzyme. Our goal is to elucidate 
the mechanism by which BluB catalyzes the oxidative fragmentation of FMN with molecular 
oxygen.  Previous studies, done by our group, with numerous substrate analogues have shown no 
enzymatic activity with BluB and conclude that the active site of BluB is highly selective for the 
native substrate. In this study, the synthesis of 6-amino-FMN and its activity with BluB are 
described. LCMS analysis of the enzymatic assays confirmed the production of 4-amino-DMB. 
This discovery suggests that active site of BluB tolerates substrate analogues with substituents at 
the 6-position and additional 6-substituted substrate analogues can be designed to provide 
mechanistic insight.  
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CHAPTER I 
INTRODUCTION 
 
Cobalamins are a family of natural products that were the first identified biomolecules to possess 
a carbon-metal bond. Cobalamins are organometallic complexes that consist of cobalt metal in an 
octahedral geometry and chelated by a cobamide structure. A cobamide is heterocyclic structure 
that consists of a tetra-pyrrole ring, known as a corrin ring and a nucleotide loop.1 The corrin 
ring coordinates equatorially and the nucleotide loop serves as the lower axial ligand.1 
Cobalamins are distinct class of cobamides in that their nucleotide loop consists of a 
benzimidazole base, usually dimethylbenzimidazole (DMB).2 The upper axial coordination site 
is the reactive site for the B12 complex and the specific enzyme the B12 coenzyme is bound to 
dictates the ligand coordinated at this site.1  Vitamin B12 denotes a cyano-substituent as the upper 
axial ligand (Figure 1).  
                            
Figure 1. The structure of vitamin B12 (cyanocobalamin). DMB is highlighted in red and the 
cyano-ligand in blue. 
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In humans, the 2 biologically active forms of cobalamin have a methyl group (Methylcobalamin) 
and the 5’-carbon of adenosine (Adenosylcobalamin) as the upper axial ligand.3 Cobalamin 
dependent enzymes catalyze intramolecular rearrangements, intermolecular methylations, and 
the reduction of NTPs.1 In humans, methionine synthase and (R)–methylmalonyl–CoA mutase 
are the only enzymes that require coenzyme B12 in order to perform their catalytic functions.1 
methionine synthase utilizes methylcobalamin, along with 5-methylfolate as coenzymes to 
catalyze the biosynthesis of methionine from homocysteine.1,4 (R)–methylmalonyl–CoA mutase 
utilizes adenosylcobalamin as its coenzyme. This enzyme is utilized in fatty-acid, amino acid, 
and carbohydrate metabolism where it catalyzes the intramolecular radical rearrangement of (R)–
Methylmalonyl–CoA to give Succinyl-CoA.1,4  The reactions catalyzed by methionine synthase 
and (R)-methylmalonyl-CoA mutase are shown below (Figure 2). 
 
Figure 2. The reactions catalyzed by the 2 B12-dependent enzymes in humans: methionine 
synthase and (R)–methylmalonyl–CoA mutase.1 
 
The de novo biosynthetic pathway of B12 requires ~ 30 enzyme-mediated steps and is restricted 
to a handful of prokaryotes.3 Complete characterization of B12’s biosynthetic pathway is nearly 
done where the biosynthesis of the nitrogenous base, DMB, of the lower nucleotide loop is the 
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last uncharacterized biosynthetic module. Recently, the BluB protein has demonstrated DMB 
synthase catalytic activity via a novel oxidative fragmentation of flavin mononucleotide (FMN) 
in the presence of O2 into DMB, alloxan, and erythrose-4-phosphate (Figure 3).2  
           
Figure 3. The oxygen-dependent reaction catalyzed by DMB synthase. 
 
BluB is the first known enzyme capable of fragmenting the isoalloxazine ring of FMN into 
DMB.2 The active site of BluB resembles the active site of enzymes within the oxidoreductases 
and mono-oxygenases family.5 This suggests that subtle structural differences in the active site 
deviate BluB’s catalytic activity from an oxidoreductase to a DMB synthase.5  
 
In this study, substrate analogues are designed and synthesized in order to probe the mechanism 
of the DMB synthase. Substrate analogues are designed to resemble the native substrate enough 
for substrate recognition by the active site but differ from the native substrate enough to trap an 
intermediate in the mechanism or lead to the formation of a shun product. The ease of 
conducting the synthetic scheme to obtain the substrate analogue is another important factor to 
consider when designing substrate analogues. Isotopic labeling studies of the BluB enzymatic 
production of DMB have lead to the current mechanism proposal (Figure 4). 
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Figure 4. Enzymatic studies conducted with FMN isotopologues, where each colored carbon 
depicts an isotopologue with 13C at that designated position. 
 
In a previous study, we examined if substrate analogues with a truncated ribityl tail displayed 
enzymatic activity. The derivative of riboflavin, hydroxyethylflavin (HEF), was synthesized was 
shown to be enzymatically inactive with BluB when introduced with either glycerol-3-phosphate 
(G3P) or glycol-2-phosphate (G2P) as co-substrates.  
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The X-Ray crystal structure of BluB with bound FMN was utilized as a guide to design 
additional substrate analogues. From the crystal structure, it was concluded that the  6- and 9- 
positions of the isoalloxazine ring were not sterically crowded by amino acid residues (Figure 
5). Thus, we hypothesize that substrate analogues with substituents at the 6- and 9- position of 
FMN will display enzymatic activity. The substrate analogue 6-nitro-FMN was initially chosen 
to test this hypothesis.  
 
Figure 5. The active site structure of BluB with the distance between the C6 (left) and C9 (right) 
FMN carbon to the nearest protein residues.   
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Scheme 1. Synthetic Methodology to synthesize 6-nitro-riboflavn and 6-amino-riboflavin The 
enzymatic methodology utilized to obtain 6-amino-FMN. 
 
To synthesize 6-nitro-FMN, 6-nitroriboflavin (NRF) was synthetically obtained and 
enzymatically phosphorylated by riboflavin kinase, shown in scheme 1. This analogue was 
originally chosen as the target molecule to probe BluB for its electron withdrawing properties. 
The π and inductive electron withdrawing character of the nitro- substituent will perturb the 
electron density of the isoalloxazine ring. This perturbation could potentially alter an enzymatic 
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step and provide an intermediate or lead to the production of a shun product. However, it became 
apparent that the 6-nitro-riboflavin species was photochemical unstable and slowly undergoes 
spontaneous photoreduction to 6-amino-riboflavin (ARF). The amino species was also obtained 
with the addition of several reducing agents. This was observed with NADH and sodium 
hyposulfite as the reducing agent (Figure 6). The facile chemical and photoreduction of NRF 
prevented the characterization of BluB with pure NRF and ARF was instead chosen as the 
substrate analogue for enzymatic characterization with BluB. The 6-amino-flavin derivatives 
were synthetically obtained via scheme 1. The 6-amino derivative will provide insight to the 
active site’s compatibility to 6-substituted analogues. If ARF is enzymatically active, further 6-
substituted substrate analogues will be designed, such as 6-cyano-FMN (CFMN), from NRF.  
 
Figure 6. Synthetic methods utilized for the reduction of 6-nitro-riboflavin to 6-amino-
riboflavin. 
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CHAPTER II 
METHODS 
 
All commercially available reagents were purchased from Sigma-Aldrich and were used without 
further purification. Riboflavin and DMB were purchased from Sigma-Aldrich. All reactions 
were performed within a fume hood. A heating mantle was used when a reaction needed to be 
heated. Removal of volatile solvents was accomplished via a rotary evaporator. The 
characterization of all substrate analogues was conducted with a 400 MHz Bruker Nuclear 
Magnetic Resonance (NMR) spectrometer, a Qstar Mass Spectrometry (MS), and a Liquid 
Chromatography Mass Spectrometer (LCMS). The biosynthesis and purification of DMB 
synthase was worked up from the vector containing the BluB gene. The biosynthesis of the DMB 
synthase protein required the purification of the BluB plasmid, the transformation of BluB into 
the E. Coli BL-21 strain, the overexpression of large cultures, and purification by Ni column 
chromatography. The enzyme was stored in an -80°C freezer until needed for enzymatic assays. 
All of the preceding procedures were conducted in LB broth media or agar containing 25 𝜇g/ml 
of ampicillin (Amp) unless stated otherwise. Enzymatic assays where prepared in a glove box 
and analyzed through HPLC. 
 
Synthesis 
6-(2’,3’,4’,5’)-pentanitro-riboflavin 
Riboflavin (1g, 2.66 mmol) was dissolved in fuming nitric acid (10 mL). Sulfuric acid (1mL) 
was slowly dropwise added to the reaction mixture at rt. The reaction mixture was stirred for 20 
hours then poured into 20-30 mL of ice water and allowed to sit in the cold room overnight. The 
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precipitate was vacuum filtered, washed with water until the pH was neutral, and dried. A dark 
orange solid (1.245 g, 2.07 mmol, 78% yield) was obtained.  
 
Figure 7. 6-(2’,3’,4’,5’)-pentanitroriboflavin 1H spectrum: (400 MHz, DMSO) δ  8.32 (s, 
chloroform), 8.08 (s, 1H), 8.00 (s, .13H)  6.12 (s, 1H), 5.80 (m, .5H), 5.42 (d, 1H), 5.05 (d,1H), 
4.84 (m, 2H), 4.67 (m, 1H), 4.15 (s, 1H), 3.29 (s, water), 3.18 (d, .5H), 2.59 (s, 3H), 2.51 (q, 
DMSO), 2.31 (s, 3H), 2.25 (s, 1H), 2.08  (s, acetone), 1.93 ppm (s, 1H). 
 
(2’,3’,4’,5’)-tetraacetyl-6-nitro-riboflavin  
6-(2’,3’,4’,5’)-pentanitroriboflavin (1 g, 1.66 mmol) was added to dry acetic anhydride (10 mL). 
The reaction mixture was placed on ice and then had sulfuric acid (1mL) added dropwise. The 
reaction mixture was stirred for 2 hours at 50-60°C. The reaction mixture was allowed to cool to 
rt and diluted with cold ethanol (75 mL). The reaction mixture was allowed to sit for 5 minutes 
followed by the addition of ice water (75 mL). The reaction mixture was concentrated in vacuo 
to approximately 30 mL and then cooled on ice. The precipitate was collected by vacuum 
filtration and the mother liquor was diluted with ethanol (15 mL) and again concentrated in 
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vacuo and placed on ice. The precipitate was again vacuum-filtered and added to the previous 
precipitate. The obtained oil diluted with water and extracted with ethyl acetate. The organic 
layer was dried with MgSO4 and concentrated in vacuo. A yellow/orange (421 mg, .715 mmol, 
43% yield) crude solid was obtained. Column Purification was conducted with 1:4 acetonitrile: 
ethyl acetate.  
 
Figure 8. (2’,3’,4’,5’)-tetraacetyl-6-nitroriboflavin 1H spectrum: (400 MHz, DMSO)  δ 7.94 
(s, 1H), 5.48 (s, 2H), 5.32 (t, 1H), 5.07 (m, 1H), 4.85 (d,1H), 4.41 (d, 1H), 4.24 (m, 1H), 3.30 (s, 
water), 2.60 (s, 3H), 2.51 (q, DMSO), 2.31 (s, 3H), 2.21 (s, 6H),  2.07 ppm (s, acetone), 2.02 (s, 
3H), 1.67 ppm (s, 3H). 
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6-nitroriboflavin4  
(2’,3’,4’,5’)-tetraacetyl-6-nitroriboflavin (70 mg, 119 𝜇mol) was dissolved  in methanolic 
ammonia (10 mL). The solution was left to stir overnight at rt. The reaction mixture was 
concentrated in vacuo, had methanol (10 mL) added and again concentrated in vacuo. The crude 
was suspended in water and lyophilized overnight to provide a red-orange crude solid (40 mg, 
95.0𝜇mol, 80% yield). 
 
Figure 9.   6-Nitro-riboflavin 1H spectrum: (400 MHz, DMSO) δ 8.15 (s, 1H), 5.11 (s, 1H), 
4.89 (m, 3H), 4.68 (d, 1H), 4.49 (s,1H), 4.26 (m, 1H), 3.66 (s, 3H), 3.47 (m, 1H), 3.33 (s, water), 
2.57 (s, 3H), 2.50 (q, DMSO), 2.30 (s, 3H), 2.08 ppm (s, acetone). 
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6-aminoriboflavin  
Was prepared in situ by the addition of sodium hyposulfite to aqueous 6-nitroriboflavin. The 
reaction was monitored by the color of the solution. The brown-green solution obtained was 
lyophilized to provide a dark-green solid. 1H NMR was not taken. 
 
Molecular Genetics 
Plasmid Extraction  
Purification of the plasmid with the BluB gene was purified from the E. Coli DH5α strain. The 
strain was streaked onto a 25  𝜇g/ml of ampicillin (Amp) LB agar plate and incubated at 37°C for 
12 hours. From this plate, a single colony was inoculated with 5 ml of 25 𝜇g/ml Amp LB media 
and placed overnight in a shaker at 37°C and 220 rpm. This culture was centrifuged for 3 minutes 
at 10,000 rpm and decanted. The pellet was resuspended in 250 𝜇l of P1 buffer. Next, 350 𝜇l of 
P2 buffer was added and inverted. Upon the appearance of a blue color, 350 𝜇l of N3 buffer was 
added and inverted until the blue color was gone. The sample was centrifuged for 10 minutes at 
13000 rpm. The supernatant was decanted to a QIA prep spin column where it was centrifuged 
for a minute. The QIA prep spin column was then washed, centrifuged for a minute at 13000 
rpm, and had the flow through discarded once with 500 𝜇l of PB buffer and twice with 750 𝜇l of 
PE buffer.  The QIA prep spin column was centrifuged for an additional 2 minutes. Finally, to 
elute the plasmid, 50 𝜇l of EB buffer was added, the QIA prep spin column was transferred to an 
eppendorf tube, and let sit for 1 minute. The QIA prep spin column was then centrifuged and the 
eluent was stored at 20°C.  
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Plasmid Transformation 
 The transformation of the BluB plasmid into BL21 competent cells was conducted by 
electroporation. The transfer of 100 𝜇l of compotent cells and of 1 𝜇l of the BluB plasmid into an 
electroporation cuvette was performed on ice and in the presence of an open flame. The 
electroporation tube was quickly dried, shocked with a 25 kV electrical pulse, and mixed with 1 
mL of media. The culture was then incubated in a shaker at 37°C for 90 minutes. Next, the 
culture was centrifuged and the media was removed until 100 𝜇l of media with the cell pellet was 
all that remained. The cell pellet was resuspended and spread on an agar plate and incubated at 
37°C for 12 hours.  
 
Protein Biochemistry 
Protein overexpression 
The overexpression of BluB was performed by inoculation of a single colony into 10 ml of 
media and grown overnight at 37°C. Approximately 5 ml of this culture was added to each of the 
two 3 L flasks containing   1.5 L of media. The culture was grown at 37°C until its optical density 
at 600 nm reached 0.600. The BluB gene was induced by the addition of .1mM IPTG while 
lowering the temperature to 30°C. The cultures were incubated for an additional 16-18 hours 
before harvesting the cells and stored at -80°C. 
 
Protein Prep 
Purification of BluB from the cell pellet was conducted via affinity chromatography. A Ni 
column was utilized with all solutions kept under ice at 4°C. The cell pellet was thawed and 
suspended in 20 mL of lysis buffer containing 2 mM DTT and 5 mg of lysozyme for 25 minutes. 
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The cells were placed under sonication for five periods of 20 seconds each. The cell lysate was 
centrifuged for 30 minutes at 17000 rpm and 4°C then passed through a 50K syringe filter. To 
prepare the Ni column for the cell extract, the Ni column was washed with 5 column volumes of 
water and then 3 column volumes of lysis buffer. The supernatant was loaded onto the column 
and the flow through was collected and stored on ice. The column was washed with a gradient of 
imidazole elution buffer. The gradient consisted of 15 ml fractions of 20, 50, 100, 150, 200, and 
250 mM imidazole elution buffer. A fraction was collected for each imidazole concentration and 
stored on ice. Each collected fraction was examined via an SDS-PAGE to determine the fraction 
that possessed the pure protein. The fraction(s) with purified protein were combined and 
centrifuged in a 10K filter tube until a total volume of 3 mL was obtained. The 3 mL of purified 
protein was loaded onto a desalting column and eluted with 3 mL of desalting buffer, which 
possessed 2 mM DTT. The purified protein was distributed into 30, 100 𝜇L aliquots, which were 
flash frozen in liquid nitrogen and stored at -80°C. Protein concentration was determined via 
absorbance with a nano-drop spectrometer at 260 nm.  
 
Figure 10. The SDS-PAGE from the purification of DMB synthase via a Ni(II) column.  
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Enzymatic Assays and HPLC Characterization 
 All of the starting materials were prepared in phosphate buffer at a pH of 7.5. Prior to 
conducting the enzymatic assays, the stocks of the starting materials had to be made. The NRF 
stock solution consisted of the extent of dissolution of NRF (1 mg) in 2 mL phosphate buffer. 
Two stocks were made where a small arbitrary amount of sodium hyposulfite was added to 1 of 
the stocks until the solution appeared faint clear yellow. This solution was exposed to O2 and 
shaken until it became a sage green-brown color. The UV-Vis spectrum of this solution was 
taken for visual confirmation of ARF spectrum, (Figure 14). The RibK stock was acquired from 
a lab member with an unknown concentration. For each RibK assay, 10 𝜇L of the RibK enzyme 
was added and contained 1 mM CTP. For the BluB assays, the concentration of NADH, FRE, 
BluB, and FMN were 2 mM, 200 nM, 100 𝜇M, and 30 𝜇M respectively. The concentration of 
AFMN was unknown because the percent conversion of ARF to AFMN was unknown. These 
assays were typically conducted with a final volume of 100 or 120 𝜇L. HPLC buffer utilized was 
10 mM ammonium acetate and the organic solvent was methanol.  
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CHAPTER III 
RESULTS 
 
Synthesis 
The synthesis of NRF was a difficult process due to its photosensitivity. It required multiple 
attempts of each reaction in scheme 1 and provided a total yield of 3.6%. Each reaction was 
monitored via TLC characterized via 1H NMR and MS to confirm the product. To synthesize 
NRF, riboflavin was first nitrated with a mixture of nitric acid and sulfuric acid. This reaction 
was unsuccessfully attempted a few times, in different conditions, with concentrated nitric acid. 
Nitration did not occur with concentrated nitric acid and required fuming nitric acid, which was 
purchased from Sigma-Aldrich. This was confirmed via the presence of the 2 aromatic protons in 
the 1H NMR spectrum of the crude product. With fuming nitric acid, the best yields were 
obtained with 10:1 ratio of fuming nitric acid to concentrated sulfuric acid with 1 g of riboflavin 
was stirred at rt for 20 hours. TLC analysis was optimized with 1:4 MeOH:EtAc as the mobile 
phase and clearly showed the presence of multiple fluorescent bands under UV light. Column 
purification was initially but identification of the desired product was too difficult, thus, it was 
decided to proceed to step 2 with the crude mixture.  
 
Figure 11. TLC characterization of TANRF and TARF. TANRF Rf = 0.6, TARF Rf = 0.4 
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Reaction 2 was the acetylation of 6-(2’,3’,4’,5’)-pentanitro-riboflavin with acetic anhydride 
under acidic conditions. The reaction was performed as described in the given procedure. 
Precipitation of the product was the most difficult part of the procedure. The original procedure 
suggests to vacuum filter the precipitate after the addition of water. However, when the reaction 
was worked up in accord with the procedure, no precipitate was initially observed. The work up 
was modified for product precipitate. To precipitate (2’,3’,4’,5’)-tetraacetyl-6-nitro-riboflavin, 
the reaction mixture was diluted with additional ethanol and water. Recrystallization in ethanol 
was also attempted as well as other solvents. The reaction mixture was concentrated in vacuo to 
approximately 30 mL and cooled on ice. This technique triggered the formation of some 
precipitate, which was vacuum filtered after precipitation appeared to stop. After in vacuo 
concentration of the mother liquor, the addition of water to the deep red oil obtained sparked the 
appearance of a bright yellow precipitate. The precipitate was vacuum filtered and the mother 
liquor was extracted with ethyl acetate dried with MgSO4, and oncentrated in vacuo. All 
fractions were combined, suspended in water and lyophilized to dryness to yield 421 mg of crude 
product. The mobile phase optimized for TLC characterization was 1:4 AcCN:EtAc with 1 drop 
of glacial acetic acid added. The 2 bands correspond to (2’,3’,4’,5’)-tetraacetyl-6-nitroriboflavin 
(TANRF) at Rf = .6  and (2’,3’,4’,5’)-tetraacetyl-riboflavin (TARF) at Rf = .35, (Figure11). 
Flash- column chromatography of 224 mg of crude (2’,3’,4’,5’)-tetraacetyl-6-nitroriboflavin 
provided(76 mg, 126𝜇mol, 7.6% yield) pure (2’,3’,4’,5’)-tetraacetyl-6-nitroriboflavin, which 
appears as a bright yellow fine-powder. 
 
The deacetylation of (2’,3’,4’,5’)-tetraacetyl-6-nitroriboflavin was accomplished with sufficient 
methanolic ammonia for dissolution. The reaction mixture was stirred overnight in the dark with 
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the round bottom wrapped in double layer aluminium foil. Work up was conducted as described 
above and crude NRF was stored in the dark at -20°C until needed for enzymatic assays. NRF 
was confirmed via 1H NMR and UV-Vis spectroscopy, and LCMS characterization. The 1H 
NMR spectrum of NRF was overlapped with the 1H NMR spectrum of riboflavin to confirm the 
presence of the nitro substituent.  The aromatic singlet of NRF should be downfield from the 2 
aromatic singlets of riboflavin, spectrum provided in appendix A. 
 
Enzymatic Assays 
 
Figure 12. HPLC chromatograms of RibK assays at 450 nm. Retention times (tr): NRF = 12.2 
min, NFMN = 10.0 min, ARF = 12.3 min, AFMN =10.2 min. 
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Initially (before the spontaneous reduction of NRF was known), HPLC purification and 
phosphorylation of NRF was attempted with NRF. Purification required 20-40 HPLC runs due to 
its low solubility in MeOH and in water, where some runs consisted of NRF dissolved in 
millipure water, phosphate buffer, and MeOH. The solvent was varied to observe if solvent 
effects would perturb the replication of the acquired chromatograms. It was found that in MeOH 
the NRF chromatograms were slightly narrower compared to aqueous solutions (data not 
shown).  Enzymatic phosphorylation of NRF with RibK was analyzed via HPLC (Figure 12). 
The peak at 10.0 min is present only in the RibK full reaction. In this assay, the NRF peak at 
12.2 min is a visually smaller peak, however, not by much when compared to the relative size of 
the new NFMN peak at 10.0 min. Enzymatic assays with a specific batch of NRF synthesized 
were conducted several times over the course of time of a few weeks. All assays were replicated 
several times over the course of 3 weeks. When the replicated assays were compared, the 
temporal spontaneous conversion of NRF and NFMN to 2 analogues species became apparent. 
The 2 new species have identical UV-Vis spectra, which significantly differ from the 
characteristic flavin spectrum seen for FMN and NRF analogues (Figure 14). In figure 12, the 
shoulder present at 12.35 min is the analogues species formed from NRF and the peak at 10.2 
min is the analogues species of NFMN. LCMS characterization of the RibK assays confirmed 
the 2 species to be ARF and AFMN with a 7.1 and 4.2 ppm error, respectfully (Figure 13).  
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Figure 13. EIC chromatograms and MS characterization of the RibK assays. EIC 1: red= 
NRF, pink = NFMN, green = AFMN; EIC 2: red = NRF pink = NFMN, blue = ARF, green = 
AFMN; EIC 3: red = NFMN, blue = AFMN for 6- amino-riboflavin. MS1:  ARF: MS2: AFMN. 
 
In figure 13, EIC 3 displays NFMN and AFMN as the red and blue trace, respectfully, where the 
AFMN peak is shifted to a higher retention time. This shift is characteristic for all species that 
undergo spontaneous nitro to amino conversion including any flavin based degradation products. 
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The spontaneous reduction of 6-nitroflavin analogues to the 6-aminoflavin analogues created 
ambiguity to the enzymatic phosphorylation of ARF to AFMN with RibK. It was not known if 
RibK only phosphorylated NRF to yield NFMN, which would then undergo spontaneous 
reduction to AFMN prior to HPLC and LCMS characterization or if ARF was a substrate for 
RibK to directly provide AFMN. To determine if ARF was a substrate for Ribk the NRF stock 
was completely converted to ARF with sodium hyposulfite prior to enzymatic phosphorylation. 
LCMS analysis of the RibK assays, EIC 1 and 2 of figure 13, confirmed the absence of the nitro 
species where the red and pink trace, present in EIC 1, provided no signal in EIC 2. The presence 
of AFMN, green trace in EIC 2, in the absence of the nitro species confirmed that ARF is indeed 
a substrate for RibK. However, like NRF, phosphorylation of ARF is slow and incomplete. The 
assays were conducted at 70°C for 2-2.5 hours and to provide the adequate conversion while the 
native substrate, riboflavin, shows full conversion at 70°C within 30 minutes (not shown). 
 
Once the nitro to amino conversion was thoroughly understood, proper characterization of BluB 
assays was possible. Enzymatic assays of NFMN with BluB were inconclusive because a 
significant amount of AFMN was always present because of the need of a reducing agent in 
order to conduct the full reaction (NFMN assays are not shown). The reduction of NRF to ARF 
was always conducted prior to enzymatic assays. Approximately 1 mg of NRF was dissolved in 
phosphate buffer (pH of 7.5) and had a small amount of sodium hyposulfite added. The 
eppendorf tube was shaken until the light yellow color representative of reduced ARF went a 
green (oxidized ARF). The UV-Vis spectrum was acquired to confirm the ARF product, (Figure 
14). The ARF solution was utilized for RibK/BluB coupled enzymatic assays. The coupled 
assays were not clean assays due to ARF and AFMN spontaneous degradation within a solution 
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as well as impurities present from the RibK assays. HPLC and LCMS characterization confirm 
AFMN is indeed a substrate for BluB. The competitive inhibition of DMB production by AFMN 
is shown in figure 15. The DMB std (purple trace) confirmed the peak with a retention time at 
17.2 min to  
 
Figure 14. UV-Vis spectrum of FMN, nitro-FMN, and amino-FMN. FMN and nitro-FMN 
has a λmax at ~ 350 nm while 6-amino-FMN has a λmin at 350 nm. 6-Amino-FMN extinction 
coefficient is 18000 M-1cm-1at 429 nm.6  
 
be DMB. This peak is absent in the AFMN full reaction assay (red trace) and present in the FMN 
full reaction control assay (brown trace). The assays were ran and quenched simultaneously to 
ensure that peak height and area are indicative of the relative amount present of a species 
between assays. In the AFMN/FMN full reaction assays less DMB is produced compared to the 
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FMN full reaction. The decrease in peak area of DMB upon the addition of AFMN was 
consistently reproduced. This signifies that FMN and AFMN must compete for the same active 
site; hence, AFMN must bind to the active site of BluB. 
 
Figure 15. HPLC chromatograms of BluB competition assays: Products at 280 nm. 
Retention times (tr): ADMB = 12.2 min, NFMN = 10.0 min, ARF = 12.3 min, AFMN =10.2 min. 
FR signifies full reaction. 
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At 450 nm, the consumption of AFMN in the presence of BluB is observed (Figure 16). The 
consumption of AFMN was inhibited by the presence of FMN while the consumption of FMN 
was inhibited by the presence of AFMN. The concentration of AFMN was varied to study if the 
consumption of FMN changed accordingly (Figure 17). The concentration of AFMN was not 
able to be determined at the time; thus, the standard concentration of AFMN present in the 
assays was labeled “X”. Assays with 2X and 4X relative  
 
Figure 16. HPLC chromatograms of BluB competition assays: Substrates at 450 nm. 
Retention times (tr): FMN = 11.0 min, AFMN = 11.4 min. 
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concentrations of AFMN were prepared. To do this, the volume of AFMN added from the RibK 
assay was adjusted and the added volume was compensated by the removal of equal volume of 
phosphate buffer. This was done to in order to not effect the concentration of other species 
present, such as FMN.  
 
Figure 17. HPLC chromatograms of BluB competition assays: substrates at 280 nm. 
Retention times (tr): FMN = 9.8 min and AFMN = 10.15 min. FR signifies full reaction. 
                                                                                                                                                             
These assays confirmed that the presence of AFMN does inhibit the consumption of FMN.  
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Figure 18 shows the HPLC chromatogram of the products from the assays shown in figure 17. 
The amount of DMB produced decreased from the AFMN FMN FR X assay to the AFMN FMN 
FR 4X assay. Thus, DMB production is inhibited by AFMN.  
 
Even though these results confirm that AFMN binds to and inhibits BluB enzymatic activity, 
products from the enzymatic fragmentation of AFMN were not observed in the HPLC 
chromatograms.  
Figure 18. HPLC chromatograms of BluB competition assays: products at 280 nm. 
Retention times (tr): DMB = 15.1 min. FR signifies full reaction. 
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Initially, the reducing agent utilized for the BluB assays was NADH. However, when 
simultaneous assays were conducted with NADH and DTT as the reducing agent it became 
apparent that NADH did not reduce AFMN adequately. When the BluB assays were reduced 
with DTT, AFMN displayed a significant increase in enzymatic activity. The increase in 
enzymatic activity with DTT allowed for sufficient AFMN product formation for HPLC 
identification (Figure 19).  
 
Figure 19. HPLC chromatograms of BluB assays: Products at 210 nm. Retention times (tr): 
ADMB = 14.2 min, DMB = 17.2 min. FR signifies full reaction. 
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AFM products were observed at 210 nm and had retention times of 14.2 min and 20.1 min. 
These 2 signals were only present in the DTT reduced enzymatic assays and absent in the NADH 
reduced assays. LCMS characterization of these assays confirmed that amino-DMB (ADMB) 
was the product of AFMN, (Figure 20). ADMB is believed to be the peak at 14.2 min and the 
dimer to be the peak at 20.1 min. The peak at 14.2 min, in figure 19, is believed to be ADMB 
because it elutes with a lower retention time with respect to DMB, (Figure 20).  
 
Figure 20. The EIC of ADMB and DMB from the AFMN/FMN competition assays reduced 
with DTT or NADH: black = ADMB (DTT), purple = ADMB (NADH), blue = DMB (DTT), 
red = DMB (NADH). 
 
The EIC for ADMB and DMB when reduced with DTT or NADH confirmed that ADMB 
formation was significantly enhanced when the BluB assays were reduced with DTT rather than 
NADH, while the production of DMB displayed a small increase with DTT when compared to 
NADH (Figure 20). The small increase in DMB production when DTT was utilized as the 
reducing agent may be attributed to the fact that reduced AFMN is a stronger reducing agent than 
reduced FMN. With DTT, a higher concentration of reduced AFMN is present within the assay 
and it may act as an additional hydride source for oxidized FMN present within the solution. 
This can result in a higher activity of reduced FMN present within the assay and cause an 
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increase in DMB production. The significant increase in the production of ADMB, when reduced 
with DTT, is attributed to an increase in activity of reduced AFMN within the assay.  
 
Although AFMN has been confirmed to be a substrate analogue for BluB, the amino substituent 
makes the species hypersensitive to oxidative degradation. This is apparent from how messy the 
HPLC chromatograms appear. Thus, if a shun product or enzymatic intermediate is formed from 
AFMN it will most likely degrade rather than accumulate into a distinct peak. Therefore, a 
method to trap and identify a shun product or an intermediate released by BluB is of high 
interest. Dansyl Chloride was chosen as the trapping agent. BluB activity assays were conducted 
with dansyl chloride to characterize any perturbations introduced by the addition of dansyl 
chloride. BluB assays with its native substrate were conducted in the absence and presence of 
dansyl chloride. Assays were also conducted with the addition of dansyl chloride after the 
enzymatic assays were quenched (Figure 21).  Dansyl chloride reduces the enzymatic activity of 
BluB when present during catalysis but does not inactivate the enzyme. Although these assays 
need to repeated and further characterized, dansyl chloride appears to be a promising trapping 
reagent because it does not denature or inactivate the protein and can be present during catalysis 
to trap any intermediate or shun product formed.  
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Figure 21. HPLC chromatograms of BluB assays in the presence of dansyl chloride: 
Products at 210 nm. Retention times (tr): FMN = 10.7 min, DMB = 17.2 min. 
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CHAPTER IV 
CONCLUSION 
 
To synthesize 6-nitro-FMN, 6-nitro-riboflavin was synthesized and characterized via 1H NMR 
and UV Vis spectroscopy, and HPLC-MS. Spontaneous reduction into 6-amino-riboflavin was 
observed via UV Vis spectroscopy, HPLC-MS. Both 6-nitro-riboflavin and 6-amino-riboflavin 
were enzymatically phosphorylated with riboflavin kinase to yield 6-nitro-FMN and 6-amino-
FMN. The addition of reducing agents (NADH and DTT) to the enzymatic assays converted 6-
nitro-FMN into 6-amino-FMN. Thus, enzymatic assays with pure 6-nitro-FMN were not 
possible. Riboflavin kinase/BluB coupled assays were conducted to examine the enzymatic 
activity of 6-amino-FMN.  Competition assays with the native substrate, FMN, confirmed that 
AFMN possessed inhibition activity. Further studies confirmed AFMN to be enzymatically 
active when reduced by DTT by the presence of amino-DMB. Amino-DMB was characterized 
via HPLC and LCMS. Further enzymatic assays need to be conducted to detect formation of any 
additional shun products or intermediate species. Thus, initial enzymatic assays with the trapping 
agent, dansyl chloride, have been conducted. In the presence of dansyl chloride, BluB appears to 
be sufficiently active. Further characterization is needed in order to properly conduct enzymatic 
assays with AFMN in the presence of dansyl chloride. 
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APPENDIX A  
 
 
Appendix 1.   6-nitroriboflavin and riboflavin 1H spectrum superimposed. 6-nitroriboflavin 
1H spectrum: (400 MHz, DMSO) δ 8.15 (s, 1H), 5.11 (s, 1H), 4.89 (m, 3H), 4.68 (d, 1H), 4.49 
(s,1H), 4.26 (m, 1H), 3.66 (s, 3H), 3.47 (m, 1H), 3.33 (s, water), 2.57 (s, 3H), 2.50 (q, DMSO), 
2.30 (s, 3H), 2.08 ppm (s, acetone); Riboflavin 1H spectrum: (400 MHz, DMSO) δ 
7.91 (s, 1H), 7.89 (s, 1H), (s, 1H), 5.07 (s, 1H),  4.93 (t, 1H), 4.81 (s, 1H),  4.77 (s, 1H), 4.62 (d, 
1H), 4.44 (t,1H), 4.24 (m, 1H), 3.63 (s, 3H), 3.45 (m, 1H), 3.29 (s, water), 2.50 (q, DMSO), 2.47 
(s, 3H 2.39), (s, 3H), 2.08 ppm (s, acetone).  
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